BRIEF—Amgen readies data from 'largest oncology pipeline in company's history'

US biotech Amgen (Nasdaq: AMGN) will present data on seven investigational assets across a range of hematologic malignancies and solid tumors at the annual meeting of the American Society of Clinical Oncology.

Notable data from the company’s oncology pipeline will include first-in-human data for investigational AMG 510, the first KRASG12C inhibitor to reach the clinical stage in patients with locally-advanced or metastatic KRASG12C mutant solid tumors.

Additional early-stage pipeline data will showcase Amgen’s bispecific T-cell engager (BiTE) platform across hematologic malignancies and solid tumors, including for the first time, in prostate cancer.

In total, the firm is advancing more than a dozen BiTE molecules, and it has called its oncology pipeline the best in Amgen’s history.